Results 131 to 140 of about 169,585 (295)

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri   +20 more
wiley   +1 more source

Voice and Speech in Atypical Parkinsonian Disorders

open access: yesMovement Disorders Clinical Practice, EarlyView.
Background Motor speech disorders are early, common, and functionally limiting features of atypical parkinsonian disorders (APDs) such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). These impairments are underrecognized and undertreated in neurology clinics.
Federico Rodriguez‐Porcel   +48 more
wiley   +1 more source

Psychiatric Comorbidity, Tic Severity and Quality of Life in Adults with Tourette's Syndrome

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Psychiatric comorbidities are common in adults with Tourette's Syndrome (TS), and appear to influence both tic severity and quality of life (QOL). Objective To assess the association between psychiatric comorbidities, tic severity and QOL in TS.
Andreas Hartmann   +9 more
wiley   +1 more source

Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain

open access: yesMovement Disorders, EarlyView.
Abstract Background Serotonergic and dopaminergic pathways are implicated in Parkinson's disease psychosis (PDP), but preliminary evidence also implicates the endocannabinoid system (ECS). Objectives We examined the association of gray matter volume loss in PDP patients with brain expression of the genes coding for CB1 (cannabinoid type 1) and CB2 ...
Sara Pisani   +3 more
wiley   +1 more source

Temporal Interference Stimulation Modulates Resting State Functional Connectivity of Motor Circuit in Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract Background Transcranial temporal interference stimulation (TIs) targeting the subthalamic nucleus (STN) is a novel noninvasive neuromodulation approach with potential to improve motor symptoms in Parkinson's disease (PD). However, its underlying neuroimaging mechanisms remain unclear.
Yongxin Xu   +19 more
wiley   +1 more source

Distinct Brain Drivers and Shared Cerebello–Cortical Input in ADCY5 and SGCE Hyperkinetic Movements

open access: yesMovement Disorders, EarlyView.
Resting‐state fMRI and effective connectivity revealed distinct cerebellar–basal ganglia–cortical interactions in ADCY5 (MxMD‐ADCY5) and SGCE (MYC/DYT‐SGCE) related movement disorders. The cerebellum modulated cortex directly in MYC/DYT‐SGCE, but indirectly via basal ganglia‐cerebellar projections in MxMD‐ADCY5, which also showed reduced subthalamic ...
Clément Tarrano   +33 more
wiley   +1 more source

Clinical Predictors of Tic‐Related Impairment in Children and Adults with Tourette Syndrome

open access: yesMovement Disorders, EarlyView.
Abstract Background Tic‐related impairment drives treatment decisions for Tourette syndrome and related tic disorders. The clinical features most strongly associated with impairment remain unclear. Objective The aim of this analysis is to identify clinical predictors of tic‐related impairment in children and adults with tic disorders in a prospective ...
Wm. Jeptha Davenport   +4 more
wiley   +1 more source

Editorial: Rising stars in cellular neuropathology 2022

open access: yesFrontiers in Cellular Neuroscience
Christian Zammit   +2 more
doaj   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

open access: yesObesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy